Literature DB >> 11413082

Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial.

G J Bech1, B De Bruyne, N H Pijls, E D de Muinck, J C Hoorntje, J Escaned, P R Stella, E Boersma, J Bartunek, J J Koolen, W Wijns.   

Abstract

BACKGROUND: PTCA of a coronary stenosis without documented ischemia at noninvasive stress testing is often performed, but its benefit is unproven. Coronary pressure-derived fractional flow reserve (FFR) is an invasive index of stenosis severity that is a reliable substitute for noninvasive stress testing. A value of 0.75 identifies stenoses with hemodynamic significance. METHODS AND
RESULTS: In 325 patients for whom PTCA was planned and who did not have documented ischemia, FFR of the stenosis was measured. If FFR was >0.75, patients were randomly assigned to deferral (deferral group; n=91) or performance (performance group; n=90) of PTCA. If FFR was <0.75, PTCA was performed as planned (reference group; n=144). Clinical follow-up was obtained at 1, 3, 6, 12, and 24 months. Event-free survival was similar between the deferral and performance groups (92% versus 89% at 12 months and 89% versus 83% at 24 months) but was significantly lower in the reference group (80% at 12 months and 78% at 24 months). In addition, the percentage of patients free from angina was similar between the deferral and performance groups (49% versus 50% at 12 months and 70% versus 51% at 24 months) but was significantly higher in the reference group (67% at 12 and 80% at 24 months).
CONCLUSIONS: In patients with a coronary stenosis without evidence of ischemia, coronary pressure-derived FFR identifies those who will benefit from PTCA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413082     DOI: 10.1161/01.cir.103.24.2928

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  159 in total

Review 1.  Optimum guidance of complex PCI by coronary pressure measurement.

Authors:  Nico H J Pijls
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 2.  Plaque sealing by coronary angioplasty.

Authors:  B Meier
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

Review 3.  Non-invasive imaging in coronary artery disease including anatomical and functional evaluation of ischaemia and viability assessment.

Authors:  M Pakkal; V Raj; G P McCann
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Secondary revascularization after CABG surgery.

Authors:  Javier Escaned
Journal:  Nat Rev Cardiol       Date:  2012-07-10       Impact factor: 32.419

5.  The Diagnostic Performance of Multifunction Cardiogram (MCG) in Functional Myocardial Ischemia.

Authors:  Tetsuma Kawaji; Takeshi Kimura
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-08-06       Impact factor: 1.468

Review 6.  The Role of Fractional Flow Reserve and Instantaneous Wave-Free Ratio Measurements in Patients with Acute Coronary Syndrome.

Authors:  Abdul Rahman Ihdayhid; Jin-Sin Koh; John Ramzy; Arnav Kumar; Michael Michail; Adam Brown; Habib Samady
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 7.  Current understanding of coronary in-stent restenosis. Pathophysiology, clinical presentation, diagnostic work-up, and management.

Authors:  T M Schiele
Journal:  Z Kardiol       Date:  2005-11

8.  Fractional flow reserve application in everyday practice: adherence to clinical recommendations.

Authors:  Katia Orvin; Tamir Bental; Alon Eisen; Hana Vaknin-Assa; Abid Assali; Eli I Lev; David Brosh; Ran Kornowski
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

Review 9.  Coronary Angiography With Pressure Wire and Fractional Flow Reserve.

Authors:  Luise Gaede; Helge Möllmann; Tanja Rudolph; Johannes Rieber; Florian Boenner; Monique Tröbs
Journal:  Dtsch Arztebl Int       Date:  2019-03-22       Impact factor: 5.594

Review 10.  Recent insights into the treatment of stable CAD : FFR-guided PCI vs. medical therapy.

Authors:  L X van Nunen; P A L Tonino
Journal:  Herz       Date:  2013-06       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.